China may approve first Covid-19 drug within weeks
- Monoclonal antibody treatment developed by Chinese and US researchers might get conditional approval by year-end, science and technology ministry daily says
- Sinopharm subsidiary meanwhile is readying clinical trials for both human and lab-made antibody treatments
Conditional approval may be given to a neutralising monoclonal antibody treatment co-developed by Chinese and US researchers by the end of the year, according to an official publication of the Ministry of Science and Technology.
01:10
Joy as US borders reopen to fully vaccinated visitors after 20 months of Covid-19 restrictions
Brii Biosciences, a multinational pharmaceutical firm based in the US and China, developed the therapy with scientists at Tsinghua University and the Third People’s Hospital of Shenzhen, Science and Technology Daily reported on Monday.
Monoclonal antibodies are laboratory-made protein molecules that can act like human antibodies. The Brii Bio treatment combines two neutralising monoclonal antibodies, BRII-196 and BRII-198, created by cloning and combining antibodies found in recovered patients in China. The combination therapy has to be administered by infusion.
Brii Bio applied to the Chinese drug regulator last month after phase 3 trials delivered promising interim data. The company was also seeking emergency use clearance in the US, a spokeswoman said.
“We hope the Chinese regulator will approve it by the end of this year,” she said.
Which drugs are most effective to treat Covid-19 patients?
Interim data from an international trial showed the medication could reduce the risk of hospitalisation and death for Covid-19 patients by 78 per cent, Brii Bio said earlier this year.
If approved, the company would first target the China and US markets, while it would also prioritise countries where it has held clinical trials, including Brazil, South Africa, Mexico, Argentina and the Philippines.
The interim results also showed that the drug was effective against Covid-19 variants such as Delta.
The treatment had already been administered to more than 800 patients in China, the spokeswoman said.
01:44
China reports record 93 coronavirus cases in single day amid Delta outbreak
Meanwhile, China National Biotec Group (CNBG), a subsidiary of state-held Sinopharm, is developing two Covid-19 drugs, one based on human immunoglobulin and the other monoclonal antibodies.
Clinical trials for the former would be carried out in the United Arab Emirates and results were expected to be available within a year, Zhang Yuntao, vice-president and chief scientist at CNBG, told state broadcaster CGTN last week.
China had earmarked 315 million yuan (US$49.3 million) for 53 research projects on developing Covid-19 drugs and therapies since the pandemic broke out almost two years ago, Science and Technology Daily reported.
So far the Chinese front runners are antibody treatments, which have to be applied through infusion or intravenous injection. The United States have already approved several monoclonal antibody medications.
Pfizer said its Paxlovid pill can cut hospitalisation and death by 89 per cent, while Merck said its molnupiravir drug can reduce the same by half.
China so far has no obvious front runners on developing oral antiviral drugs. The report by Science and Technology Daily said the country’s researchers were exploring three routes – blocking the virus’ entry into human cells, inhibiting virus replication, and adjusting the human immune system.
Zero Covid still less costly, China’s top expert Zhong Nanshan says
Specific criteria spelt out by Zhong for a return to pre-pandemic normal included keeping the case fatality rate at 0.1 per cent and the coronavirus’ reproduction number within the range of 1.0 to 1.5.
“But realising these criteria is premised upon carrying out mass inoculation, establishing herd immunity, making community epidemic control the new normal and developing effective drugs [for Covid-19 treatment],” Southern Daily newspaper quoted him as saying in Guangzhou.